Table 1.
Strain | Source | Etest MIC (μg/ml)d |
YycG change | LiaFSR changec | Reference | |
---|---|---|---|---|---|---|
DAP | VAN | |||||
S447a | Urine | 3 | 256 | No | No | 7 |
R446a | Blood | 16 | 16 | Yes | No | 7 |
S447ClsR218Q | Allelic replacement of cls in S447 | 3 | 256 | No | No | This work |
TX0133ab | Blood | 3 | 256 | Yes | Yes | 21 |
TX0133a.4 | In vitro derivative of TX0133a obtained outside the inhibition zone of a vancomycin Etest strip | 3 | 1 | Yes | Yes | 21 |
TX0133a.1 | In vitro derivative of TX0133a obtained within the inhibition zone of a vancomycin Etest strip | 4 | 512 | No | Yes | 21 |
TX0133bb | Blood after DAP therapy | 4 | 2 | No | Yes | 21 |
TX0133cb | Blood after VAN therapy | 3 | 512 | No | Yes | 21 |
Clinical strain pair from a patient who developed urinary tract infection (S447) and bacteremia (R446) (7).
Clinical strain set of DAP-susceptible isolates from a different patient with E. faecium endocarditis who failed DAP monotherapy (21).
S105N substitution in LiaS.
DAP, daptomycin; VAN, vancomycin.